Paradigm Biocapital Advisors LP 13F: Portfolio & Holdings
This page tracks the 13F filings for Paradigm Biocapital Advisors LP (SEC CIK 0001855655), a NEW YORK-based hedge fund managing $4.90 billion across 35 reported positions as of Q1 2026, per its quarterly SEC Form 13F-HR filing. As evidenced by the Q1 2026 13F report, Paradigm Biocapital Advisors allocates 99.3% of 13F-reported holdings to Healthcare — largest sector exposure.
By portfolio weight, the top holdings are ARCELLX INC (ACLX) at 13.55%, REVOLUTION MEDICINES INC (RVMD) at 13.22%, and NUVALENT INC (NUVL) at 11.15%. Ranked by the share of each peer fund's 13F equity portfolio that overlaps with Paradigm Biocapital Advisors's disclosed positions as of Q1 2026, the closest peers are Darwin Global Management 13F (95.2%), Caligan 13F (47.2%), and Frazier Life Sciences 13F (38.8% overlap).
Most recently, the manager opened a new position in INSMED INCORPORATED (INSM) (4.19%), fully exited CIDARA THERAPEUTICS INC (SYN_171757206) , added to TERNS PHARMACEUTICALS INC (TERN) (+173.55% shares), and trimmed UROGEN PHARMA LTD (URGN) (-61.91% shares). View the full Q1 2026 allocation shift and trading report →
- 13F AUM
- $4.9B
- Equity Positions
- 35
- Top-10 Concentration
- 67.6%
- Largest Sector · 99.3%
- Healthcare
- Longest-Held Position · 18 qtrs
- VRDN
- Median Holding Period
- 3 Qtrs
Top 10 Holdings — Paradigm Biocapital Advisors — Q1 2026
Largest 13F positions disclosed by Paradigm Biocapital Advisors, ranked by portfolio weight. Full multi-quarter history and the broader institutional holder base for each ticker linked per row.
| # | Issuer | Ticker | Sector | Weight | Position Value | Detail |
|---|---|---|---|---|---|---|
| 1 | ARCELLX INC | ACLX | Healthcare | 13.55% | $663.0M | Position History All Holders |
| 2 | REVOLUTION MEDICINES INC | RVMD | Healthcare | 13.22% | $647.3M | Position History All Holders |
| 3 | NUVALENT INC | NUVL | Healthcare | 11.15% | $545.5M | Position History All Holders |
| 4 | VAXCYTE INC | PCVX | Healthcare | 5.69% | $278.5M | Position History All Holders |
| 5 | EDGEWISE THERAPEUTICS, INC. | EWTX | Healthcare | 4.74% | $232.0M | Position History All Holders |
| 6 | GENMAB A/S | GMAB | Healthcare | 4.37% | $213.8M | Position History All Holders |
| 7 | INSMED INCORPORATED NEW | INSM | Healthcare | 4.19% | $205.1M | Position History All Holders |
| 8 | TARSUS PHARMACEUTICALS INC | TARS | Healthcare | 3.67% | $179.7M | Position History All Holders |
| 9 | BELITE BIO INC NEW | BLTE | Healthcare | 3.63% | $177.7M | Position History All Holders |
| 10 | ERASCA INC | ERAS | Healthcare | 3.44% | $168.2M | Position History All Holders |
View Paradigm Biocapital Advisors's Q1 2026 allocation shift and trading report →
Portfolio composition
Sectors, concentrations, and a tap-through treemap of every position in the fund's latest 13F.
Quarterly shiftsQ1 2026 vs previous quarter
Top movers in Paradigm Biocapital Advisors's Form 13F versus the prior reporting quarter. Δ Weight is the change in portfolio weight (percentage points); Δ Shares is the percent change in share count.
| Company | Ticker | Δ Weight | Δ Shares |
|---|---|---|---|
| TERNS PHARMACEUTICALS INC | TERN | +1.51% | +173.55% |
| VIRIDIAN THERAPEUTICS, INC. | VRDN | +0.06% | +118.20% |
| ORUKA THERAPEUTICS INC | ORKA | +0.94% | +35.67% |
| SPYRE THERAPEUTICS, INC. | SYRE | +0.73% | +33.40% |
| LEXEO THERAPEUTICS INC | LXEO | +-0.54% | +29.83% |
| Company | Ticker | Δ Weight | Δ Shares |
|---|---|---|---|
| UROGEN PHARMA LTD | URGN | -2.18% | -61.91% |
| BRIDGEBIO ONCOLOGY THERAPEUT | BBOT | -0.60% | -61.61% |
| SCHOLAR ROCK HLDG CORP | SRRK | -2.38% | -59.96% |
| ABIVAX S.A. | ABVX | -3.36% | -45.50% |
| ORIC PHARMACEUTICALS INC | ORIC | -0.09% | -29.15% |
| Company | Ticker | New weight |
|---|---|---|
| INSMED INCORPORATEDNEW | INSM | 4.19% |
| BELITE BIO INCNEW | BLTE | 3.63% |
| CENTESSA PHARMACEUTICALS PLCNEW | CNTA | 2.90% |
| CYTOKINETICS INCNEW | CYTK | 1.99% |
| TANGO THERAPEUTICS INCNEW | TNGX | 1.71% |
| Company | Ticker | Prev weight |
|---|---|---|
| CIDARA THERAPEUTICS INC | SYN_171757206 | 4.49% |
| CRINETICS PHARMACEUTICALS, INC. | CRNX | 2.76% |
| BRIDGEBIO PHARMA INC | BBIO | 1.40% |
| OCULAR THERAPEUTIX INC | OCUL | 0.95% |
Waterfall analysis
Top movers versus the prior reporting quarter. Left panel bridges market-value change in USD millions; right panel shows share-count change in %.
Holding period analytics
Distribution of holding periods for all 122 stocks the fund has ever held (up to selected quarter):
Which Funds Hold a Similar Portfolio to Paradigm Biocapital Advisors?
Ranked by percentage of the peer fund's 13F equity portfolio that overlaps with Paradigm Biocapital Advisors's positions in Q1 2026.
| # | Fund | Shared Positions | Overlap % |
|---|---|---|---|
| 1 | Darwin Global Management 13F | 4 | 95.2% |
| 2 | Caligan 13F | 9 | 47.2% |
| 3 | Frazier Life Sciences 13F | 8 | 38.8% |
| 4 | Deep Track 13F | 15 | 32.4% |
| 5 | Deerfield 13F | 9 | 27.1% |
How Has Paradigm Biocapital Advisors's AUM Changed Over Time?
Quarterly 13F-reported AUM for Paradigm Biocapital Advisors, derived from aggregate reported position market values disclosed to the U.S. SEC.
| Quarter | 13F AUM (USD) | QoQ Change |
|---|---|---|
| Q4 2021 | $350M | — |
| Q1 2022 | $378M | +0.03B |
| Q2 2022 | $502M | +0.12B |
| Q3 2022 | $710M | +0.21B |
| Q4 2022 | $852M | +0.14B |
| Q1 2023 | $1.1B | +0.20B |
| Q2 2023 | $1.2B | +0.18B |
| Q3 2023 | $1.5B | +0.23B |
| Q4 2023 | $2.1B | +0.67B |
| Q1 2024 | $2.8B | +0.71B |
| Q2 2024 | $2.6B | -0.23B |
| Q3 2024 | $2.9B | +0.24B |
| Q4 2024 | $2.9B | +0.02B |
| Q1 2025 | $2.2B | -0.70B |
| Q2 2025 | $2.3B | +0.17B |
| Q3 2025 | $3.4B | +1.04B |
| Q4 2025 | $3.7B | +0.35B |
| Q1 2026 | $4.9B | +1.16B |
Methodology & FAQ
How We Track Paradigm Biocapital Advisors Holdings
Our data is systematically aggregated directly from quarterly Form 13F-HR disclosures submitted to the U.S. Securities and Exchange Commission (SEC).
- Who Must File (Reporting Threshold): This dataset includes filings from U.S. institutional investment managers, hedge funds, mutual funds, university endowments, and family offices managing at least $100 million in Section 13(f) securities (including equities, options, convertibles, ETFs, and warrants).
- What is Included (Data Scope): By regulation, 13F filings include long positions in U.S. exchange-listed stocks, ETFs, shares of closed-end investment companies, and convertible debt, as defined in the SEC's official Section 13(f) securities list . For listed options (calls/puts) the reported value is based on the notional value.
- Portfolio Weight Explained (Metric Definition): “Portfolio Weight” shows how much of a fund's total reported 13F portfolio value (excluding listed options) is allocated to a specific position on the reporting date.
- How to Use This Data (Interpretation): Quarter-over-quarter changes in shares and portfolio weight reflect a combination of active trading and market price movements. These are descriptive metrics of fund allocation, not explicit buy or sell signals.
What does Paradigm Biocapital Advisors's 13F filing disclose about their portfolio?
A Form 13F-HR filed by Paradigm Biocapital Advisors with the U.S. SEC discloses all long positions in Section 13(f) securities — U.S.-listed equities, ETFs, closed-end funds, and listed put/call options — held at quarter-end with a market value of at least $200,000 or 10,000 or more shares. Pactolio aggregates these filings to surface Paradigm Biocapital Advisors’s reported portfolio weights, share counts, and quarter-over-quarter allocation shifts in a structured format. The filing represents a point-in-time snapshot of disclosed long-side exposure, not a real-time or complete view of the fund’s total book.
How do you measure conviction in Paradigm Biocapital Advisors's portfolio allocations?
Conviction is measured by portfolio weight — the percentage of Paradigm Biocapital Advisors’s total reported 13F market value allocated to a given position — rather than by absolute share count or dollar value alone. A position representing a disproportionately large share of the fund’s disclosed book signals high-conviction allocation, regardless of whether it ranks among the fund’s largest absolute holdings. Tracking how that weight changes quarter-over-quarter separates active reallocation decisions from passive price appreciation drift.
What is excluded from Paradigm Biocapital Advisors's 13F — short positions, swaps, and derivatives?
SEC Form 13F requires disclosure of long positions only. Specifically excluded are: short interest, total return swaps, credit default swaps, and all OTC derivatives — none of which appear in 13F filings regardless of position size. Listed put and call options must be disclosed but are excluded from portfolio weight calculations on this platform so that reported weights reflect direct equity exposure and remain comparable across filers. This means Paradigm Biocapital Advisors’s 13F represents the reported long book, which may differ materially from its net economic exposure.
When is Paradigm Biocapital Advisors's 13F data available, and how large is the reporting lag?
Investment managers must submit Form 13F within 45 calendar days of each quarter-end (the T+45 deadline). Pactolio ingests filings directly from SEC EDGAR as they are published — managers who file early appear in our system before the deadline, while late filers are captured on their actual filing date. The quarter label shown at the top of this page reflects the most recently processed 13F cycle for Paradigm Biocapital Advisors. The inherent reporting lag means the data always reflects positions as of the prior quarter-end, not current holdings.
Who must file a Form 13F with the SEC, and does Paradigm Biocapital Advisors qualify?
Under SEC Rule 13f-1, any investment manager — including hedge funds, family offices, registered investment advisers, pension funds, and university endowments — that exercises investment discretion over $100 million or more in Section 13(f) securities at any point during a calendar year must file Form 13F for that year. Paradigm Biocapital Advisors meets this threshold, which is why its holdings are publicly disclosed and accessible on this platform. The $100 million threshold is evaluated on a rolling basis, meaning new filers can enter and existing filers can exit the disclosure regime as AUM crosses that boundary.